Financial Snapshot
Revenues
Revenues
Revenue YoY Change
Revenues
Expenses
Cost Of Revenues
Gross Profit
Gross Profit Margin
Gross Profit
Selling, General & Admin Expense
Research & Development
Depreciation, Depletion & Amortization
SGA Expense to Gross Profit Ratio
R&D To Gross Profit Ratio
DDA To Gross Profit Ratio
Operating Expenses Total
Operating Profits/Loss
Operational Expenses
Interest Expenses
Interest Expenses To Operating Income %
Other Expense/Income
Interest & Other Expense/Income
Income/Loss
Pretax Income
Income Tax
Net Profits/Loss
Pretax Income YoY Change
Income Tax Rate
Net Profits/Loss YoY Change
Basic EPS
Net Income To Revenue Ratio
Pretax & Net Income
Assets & Liabilities
Cash & Short-Term Investments
Cash & Equivalents
Cash To Operating Expenses Ratio
Inventory
Receivables
Total Short-Term Assets
Property, Plant And Equipment
Long-Term Investments
Total Long-Term Assets
Total Assets
Net Income To Total Assets Percentage
Accounts Payable
Short-Term Debt
Long Term Debt Due
Total Short-Term Liabilities
Long-Term Debt
Other Long-Term Liabilities
Total Long-Term Liabilities
Total Liabilities
Short-Term To Long-Term Debt Ratio
Short-Term Assets To Debt Ratio
Long-Term Debt To Net Income Ratio
Assets & Liabilities
Ownership
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares
Stock Issuance & Repurchase
Ownership Data
Return On Shareholders' Equity
Book Value
Free Cash Flow
Free Cash Flow YoY
Free Cash Flow Margin
Dividends
Dividends
Stock Price
About Prime Medicine, Inc.
Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 234 full-time employees. The company went IPO on 2022-10-20. The company deploys its Prime Editing platform, a gene editing technology, to develop a new class of differentiated, one-time genetic therapies. The company is engaged in developing Prime Editors as a new class of therapeutics with transformative potential to expand the application of curative precision genetic medicines. The company has built a diversified portfolio of investigational therapeutic programs organized around core areas of focus, namely hematology and immunology, liver, lung, ocular and neuromuscular. The programs within its other areas of focus are on earlier stages of preclinical development and include Liver programs, such as Wilson's disease and glycogen storage disease 1b; Lung program, such as Cystic fibrosis; Ocular program, such as Retinitis pigmentosa caused by Rhodopsin mutations, and Neuromuscular programs, including Friedreich's ataxia and myotonic dystrophy type 1.
Industry: Biological Products, (No Diagnostic Substances) Peers: Vericel Corp CHINOOK THERAPEUTICS, INC. Avidity Biosciences, Inc. Day One Biopharmaceuticals, Inc. DYNAVAX TECHNOLOGIES CORP IOVANCE BIOTHERAPEUTICS, INC. Keros Therapeutics, Inc. RECURSION PHARMACEUTICALS, INC. Protagonist Therapeutics, Inc
